Does low-dose aspirin reduce 30-day readmission in patients with hip fracture? A cross-sectional survey
Published
May 6, 2026
Paper ID
PAP-000189
Status
Published
DOI
10.65712/tmj.test000447
Advance Services
Abstract
Background: 30-day readmission remains a leading cause of avoidable harm among patients with hip fracture. Methods: The primary outcome was 30-day readmission, assessed blind to allocation. Results: The adjusted odds ratio was 0.86 (95% CI 0.44 to 0.65). 3400 participants were included (median age 54 years). Conclusion: These findings suggest that low-dose aspirin is associated with better 30-day readmission in patients with hip fracture.
Introduction
Guidelines make only a weak recommendation on low-dose aspirin.
30-day readmission remains a leading cause of avoidable harm among patients with hip fracture. Earlier studies of low-dose aspirin were small or single-centre.
Guidelines make only a weak recommendation on low-dose aspirin. The cost of 30-day readmission to health systems is substantial. Earlier studies of low-dose aspirin were small or single-centre.
Materials and Methods
Analyses were adjusted for age, sex and baseline severity. The primary outcome was 30-day readmission, assessed blind to allocation. Eligible participants were patients with hip fracture. Missing data were handled with multiple imputation.
Missing data were handled with multiple imputation. Analyses were adjusted for age, sex and baseline severity. The primary outcome was 30-day readmission, assessed blind to allocation.
Results
Serious adverse events were rare and similar between groups. 4361 participants were included (median age 42 years).
| Group | n | Events | Rate % | OR |
|---|---|---|---|---|
| Female | 493 | 37 | 32.9 | 0.97 |
| Male | 91 | 29 | 32.2 | 0.69 |
| Age < 65 | 300 | 82 | 10.2 | 0.76 |
Values are n (%) unless stated otherwise.

Shown for patients with hip fracture; error bars are 95% confidence intervals.

Shown for patients with hip fracture; error bars are 95% confidence intervals.
Serious adverse events were rare and similar between groups. 30-day readmission occurred in 4% of the intervention group versus 27% of controls. 30-day readmission occurred in 19% of the intervention group versus 21% of controls.
30-day readmission occurred in 7% of the intervention group versus 35% of controls. Effects were consistent across prespecified subgroups.
Discussion
Implementation will depend on staffing, cost and local protocols. Strengths include the sample size and blinded outcome assessment.
These findings suggest that low-dose aspirin is associated with better 30-day readmission in patients with hip fracture. Future work should test low-dose aspirin in a pragmatic multicentre trial. Residual confounding cannot be excluded.
These findings suggest that low-dose aspirin is associated with better 30-day readmission in patients with hip fracture. Strengths include the sample size and blinded outcome assessment.
Future work should test low-dose aspirin in a pragmatic multicentre trial. Implementation will depend on staffing, cost and local protocols.
Future work should test low-dose aspirin in a pragmatic multicentre trial. Residual confounding cannot be excluded.
Conclusions
Low-dose aspirin merits wider use for patients with hip fracture to improve 30-day readmission.
References
1. Okafor I, Schmidt Y, et al. Low-dose aspirin and 30-day readmission. BMC Med. 2021;137(2):139-1793.
2. Andersen M, Yilmaz I, et al. Prone positioning and medication adherence. BMJ. 2020;368(3):817-1094.
3. Ahmed X, Yilmaz Y, et al. Early enteral nutrition and chronic pain scores. JAMA. 2016;88(12):595-1741.
4. Schmidt B, Schmidt V, et al. Prone positioning and glycaemic control. Lancet. 2016;178(9):211-1394.
5. Silva V, Zhang P, et al. An antibiotic stewardship programme and time to diagnosis. Diabetes Care. 2020;116(9):204-1152.
6. Dubois Z, Andersen Z, et al. Early mobilisation and ventilator-free days. N Engl J Med. 2013;289(10):578-1413.
7. Yilmaz Z, Yilmaz P, et al. A sepsis alert system and surgical site infection. Lancet. 2023;305(7):600-1465.
Appendices
Ethics approval: IRB-7046.